🎉 M&A multiples are live!
Check it out!

Jasper Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Jasper Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Jasper Therapeutics Overview

About Jasper Therapeutics

Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.


Founded

2019

HQ

United States of America
Employees

64

Financials

LTM Revenue $1.3M

LTM EBITDA -$81.0M

EV

-$6.7M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Jasper Therapeutics Financials

Jasper Therapeutics has a last 12-month revenue of $1.3M and a last 12-month EBITDA of -$81.0M.

In the most recent fiscal year, Jasper Therapeutics achieved revenue of n/a and an EBITDA of -$74.9M.

Jasper Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Jasper Therapeutics valuation multiples based on analyst estimates

Jasper Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$67.8M -$74.9M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$37.7M -$64.5M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Jasper Therapeutics Stock Performance

As of April 15, 2025, Jasper Therapeutics's stock price is $4.

Jasper Therapeutics has current market cap of $63.1M, and EV of -$6.7M.

See Jasper Therapeutics trading valuation data

Jasper Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$6.7M $63.1M XXX XXX XXX XXX $-4.92

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Jasper Therapeutics Valuation Multiples

As of April 15, 2025, Jasper Therapeutics has market cap of $63.1M and EV of -$6.7M.

Jasper Therapeutics's trades at -5.3x LTM EV/Revenue multiple, and 0.1x LTM EBITDA.

Analysts estimate Jasper Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Jasper Therapeutics and 10K+ public comps

Jasper Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$6.7M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 0.1x XXX XXX XXX
P/E -0.9x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.1x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Jasper Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Jasper Therapeutics Valuation Multiples

Jasper Therapeutics's NTM/LTM revenue growth is 180%

Jasper Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.2M for the same period.

Over next 12 months, Jasper Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Jasper Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Jasper Therapeutics and other 10K+ public comps

Jasper Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 10% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Jasper Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Genomics & Personalized Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Jasper Therapeutics M&A and Investment Activity

Jasper Therapeutics acquired  XXX companies to date.

Last acquisition by Jasper Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Jasper Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Jasper Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Jasper Therapeutics

When was Jasper Therapeutics founded? Jasper Therapeutics was founded in 2019.
Where is Jasper Therapeutics headquartered? Jasper Therapeutics is headquartered in United States of America.
How many employees does Jasper Therapeutics have? As of today, Jasper Therapeutics has 64 employees.
Who is the CEO of Jasper Therapeutics? Jasper Therapeutics's CEO is Mr. Ronald A. Martell.
Is Jasper Therapeutics publicy listed? Yes, Jasper Therapeutics is a public company listed on NAS.
What is the stock symbol of Jasper Therapeutics? Jasper Therapeutics trades under JSPR ticker.
When did Jasper Therapeutics go public? Jasper Therapeutics went public in 2021.
Who are competitors of Jasper Therapeutics? Similar companies to Jasper Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Jasper Therapeutics? Jasper Therapeutics's current market cap is $63.1M
What is the current revenue of Jasper Therapeutics? Jasper Therapeutics's last 12-month revenue is $1.3M.
What is the current EBITDA of Jasper Therapeutics? Jasper Therapeutics's last 12-month EBITDA is -$81.0M.
What is the current EV/Revenue multiple of Jasper Therapeutics? Current revenue multiple of Jasper Therapeutics is -5.3x.
What is the current EV/EBITDA multiple of Jasper Therapeutics? Current EBITDA multiple of Jasper Therapeutics is 0.1x.
Is Jasper Therapeutics profitable? Yes, Jasper Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.